Literature DB >> 12706181

Development of common data elements: the experience of and recommendations from the early detection research network.

Marcy D Winget1, John A Baron, Margaret R Spitz, Dean E Brenner, Denise Warzel, Heather Kincaid, Mark Thornquist, Ziding Feng.   

Abstract

There have been an increasing number of large research consortia in recent years funded by the National Cancer Institute (NCI) to facilitate multi-disciplinary, multi-institutional cancer research. Some of these consortia have central data collection plans similar to a multi-center clinical trial whereas others plan to store data locally and pool or share the data at a later date. Regardless of the goal of the consortium, there is a need to standardize the way certain data are collected and stored, transferred, or reported across the institutions involved. This communication is a report of the process and current status of the development of common data elements (CDEs) by the Early Detection Research Network (EDRN). The development of the CDEs involved several stages with each stage requiring input from multi-disciplinary experts in oncology, epidemiology, biostatistics, pathology, informatics, and study coordination. An effort was made to be consistent with other consortia developing similar CDEs and to follow data standards when available. Initial focus was on identifying the minimum data that would be necessary to collect on all EDRN study participants and EDRN specimens. There are currently CDEs in the development or pilot phase for eight different organ sites and 13 different types of specimen procurements and plans to develop CDEs for 12 or more additional types of specimens.

Entities:  

Mesh:

Year:  2003        PMID: 12706181     DOI: 10.1016/s1386-5056(03)00005-4

Source DB:  PubMed          Journal:  Int J Med Inform        ISSN: 1386-5056            Impact factor:   4.046


  23 in total

1.  Data standards in diabetes patient registries.

Authors:  Rachel L Richesson
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

Review 2.  Developing proteomic biomarkers for bladder cancer: towards clinical application.

Authors:  Maria Frantzi; Agnieszka Latosinska; Leif Flühe; Marie C Hupe; Elena Critselis; Mario W Kramer; Axel S Merseburger; Harald Mischak; Antonia Vlahou
Journal:  Nat Rev Urol       Date:  2015-05-26       Impact factor: 14.432

3.  [RD] PRISM Library: Patient Registry Item Specifications and Metadata for Rare Diseases.

Authors:  Rachel Richesson; Denise Shereff; James Andrews
Journal:  J Libr Metadata       Date:  2010-04-01

4.  Unleashing the value of Common Data Elements through the CEDAR Workbench.

Authors:  Martin J O'Connor; Denise B Warzel; Marcos Martínez-Romero; Josef Hardi; Debra Willrett; Attila L Egyedi; Aras Eftekhari; John Graybeal; Mark A Musen
Journal:  AMIA Annu Symp Proc       Date:  2020-03-04

Review 5.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

Review 6.  Statistical consideration for clinical biomarker research in bladder cancer.

Authors:  Shahrokh F Shariat; Yair Lotan; Andrew Vickers; Pierre I Karakiewicz; Bernd J Schmitz-Dräger; Peter J Goebell; Nuria Malats
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

7.  Demonstrating "collect once, use many"--assimilating public health secondary data use requirements into an existing Domain Analysis Model.

Authors:  Cynthia Barton; Crystal Kallem; Patricia Van Dyke; Donald Mon; Rachel Richesson
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

8.  Age-group differences in human papillomavirus types and cofactors for cervical intraepithelial neoplasia 3 among women referred to colposcopy.

Authors:  Julia W Gargano; Rosane Nisenbaum; Daisy R Lee; Mack T Ruffin; Martin Steinau; Ira R Horowitz; Lisa C Flowers; Talaat S Tadros; George Birdsong; Elizabeth R Unger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10-25       Impact factor: 4.254

9.  Assays for prostate cancer : changing the screening paradigm?

Authors:  Jens Hansen; Michael Rink; Markus Graefen; Shahrokh Shariat; Felix K-H Chun
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

10.  A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research.

Authors:  Rémy Choquet; Meriem Maaroufi; Albane de Carrara; Claude Messiaen; Emmanuel Luigi; Paul Landais
Journal:  J Am Med Inform Assoc       Date:  2014-07-18       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.